Dendritic Cell Based Therapy of Metastatic Breast Cancer

Inclusion Criteria: Histologically proven progressive metastatic or locally advanced breast cancer No standard treatment indicated Age: > 18 WHO-Performance Status 0-1 At least tone measurable tumor lesions according to the RECIST criteria. Expression of the HLA-A2 tissue type Life expectancy more than 3 months Acceptable CBC and blood chemistry results Written informed consent Exclusion Criteria: Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin). Patients with metastatic disease in the central nervous system (CNS). Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure. Patients with acute or chronic infection including HIV, hepatitis and tuberculosis. Patients who are pregnant. Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial. Patients who receive corticosteroids or other immunosuppressive agents. Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.